Researchers called for standardized health outcome descriptors to help bridge communication gaps in rheumatology care and ...

Caregivers and patients with acute leukemia face unique challenges, prioritizing treatment preferences that impact quality of ...

Revumenib, an oral targeted therapy for rare leukemias, is projected to be cost-neutral for health plans over 3 years, ...